Press Release

21 March 2022

In February 2022, HitGen Inc. signed an agreement with Eli Lilly and ConfometRx to begin work on a GPCR target.

In February 2022, HitGen Inc. signed an agreement with Eli Lilly and ConfometRx to begin work on a GPCR target.
21 March 2022

Lipigon and HitGen announce achievement of an important milestone in dyslipidemia project

Lipigon Pharmaceuticals AB ("Lipigon") and HitGen Inc. (“HitGen”) today announced that they have identified novel small molecules that could be starting points for developing drugs targeting dyslipidemia and cardiovascular disease.
17 March 2022

HitGen Announces Research Collaboration Focused on DNA-Encoded Library Based Drug Discovery

CHENGDU, China, March 17, 2022 – Shanghai Stock Exchange listed company HitGen Inc. (“HitGen”) today announced that it has entered into a research collaboration agreement with Howard Hughes Medical Institute (“HHMI”) and Duke University. The Principal Investigators for HHMI and Duke University who will oversee the collaboration will be Dr. Robert J. Lefkowitz, a James B. Duke Professor of Medicine and Professor of Biochemistry and Chemistry at the Duke University Medical Center,
25 February 2022

HitGen has successfully completed a three-year collaboration with MTPC to discover novel hit compounds for multiple drug targets

Chengdu, China, February 25, 2022 – HitGen Inc. (“HitGen”), a Shanghai Stock Exchange STAR-listed company, today announced that the company has successfully completed a three-year drug discovery research collaboration with Mitsubishi Tanabe Pharma Corporation (“MTPC”), a Japanese pharmaceutical company with the mission of “Creating hope for all facing illness”.
23 December 2021

Lipigon and HitGen extend collaboration agreement on dyslipidemia project

Chengdu, China December 23, 2021 Lipigon Pharmaceuticals AB (”Lipigon”), developer of therapeutics for lipid-related diseases, and HitGen Inc. (”HitGen”) have extended the collaboration agreement on the development of small molecules for the treatment of dyslipidemia and cardiometabolic disease until 7 July 2024.
05 November 2021

HitGen and Cambridge Molecular announce a strategic partnership, bringing together DNA-Encoded Libraries and Deep Learning

Chengdu, China, and Cambridge, United Kingdom, 5 November 2021 – HitGen Inc. (688222.SH) and Cambridge Molecular are pleased to announce an exclusive alliance, introducing DeepDELve 2 – Cambridge Molecular’s highly optimised DEL-specific deep learning system – as an addition to HitGen’s world-leading DEL discovery platform, with over 1 trillion drug-like small molecules.
01 November 2021

Vernalis Research - a fully owned subsidiary of HitGen Inc - and Hannibal Innovation announce the creation of Dania Therapeutics ApS

Chengdu, China, 1 November 2021 – Vernalis Research (“Vernalis”), a fully owned subsidiary of HitGen Inc., and Hannibal Innovation ApS (“Hannibal”) are pleased to announce the creation of Dania Therapeutics ApS (“Dania”) to discover small molecules inhibitors against new undisclosed oncology targets.
29 October 2021

Infographic|HitGen FY2021 Q3 Report

Infographic|HitGen FY2021 Q3 Report
02 September 2021

Veritas In Silico and HitGen Announce Research Collaboration Focused on DNA-Encoded Library Based RNA-targeting small molecule Drug Discovery

CHENGDU, China, Sep 2nd, 2021-- Shanghai Stock Exchange listed company HitGen Inc. (“HitGen”) and Veritas In Silico Inc. (“Veritas In Silico”), a Tokyo-based private company, today announced that they have entered into a research collaboration agreement to discover small molecule compounds against RNA targets. Veritas In Silico will apply its drug discovery platform, ibVIS, to identify certain RNA targets that are of interest to Veritas In Silico.
31 August 2021

Infographic | HitGen FY2021 Mid-term Report

HitGen FY2021 Mid-term Report

News

Press Release

Thanks for reading!